JNJ vs NVS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
JNJ · Johnson & Johnson$276.22 ▲ 1.43%
NVS · Novartis AG$162.55 ▲ 0.38%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- JNJ +49.9%
- NVS +31.7%
Head to head
| Metric | JNJ | NVS |
|---|---|---|
| Price | $276.22 | $162.55 |
| Change today | ▲ 1.43% | ▲ 0.38% |
| Market cap | $664.95B | $307.00B |
| Return, 3 months | +6.0% | +3.7% |
| Return, year to date | +35.6% | +21.5% |
| Return, 1 year | +51.4% | +32.5% |
| P/E (TTM) | 42.0 | 31.0 |
| P/B | 8.2 | 8.2 |
| P/E percentile vs own 5y | 100th | 97th |
| Dividend yield | 1.91% | 2.92% |
| Revenue growth (YoY, latest qtr) | +5.9% | +4.7% |
| Net profit growth (YoY) | -95.9% | -69.6% |
| Gross margin | 67.6% | 74.9% |
| Operating margin | 25.7% | 25.2% |
| Net margin | 16.2% | 17.5% |
| Return on equity | – | 24.6% |
| Analyst target vs. price | +5.2% | +5.5% |
| Analyst buy share | 71% | 67% |
| RSI (14) | 59 | 65 |
| 30-day volatility | 30.6% | 25.9% |
| Max drawdown, 1 year | -11.0% | -16.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JNJ is the largest of the group by market value.
- JNJ has returned the most over the past year.
- NVS carries the lowest trailing P/E.
- NVS pays the highest dividend yield.
- JNJ is growing revenue fastest.
- NVS keeps the most profit per dollar of sales.
- NVS has been the calmest stock over the last 30 days.